Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: The face recognition and identification system comprises a camcorder configured to capture facial image with and without facial accessories; an image pre-processing unit to normalize the captured facial image thereby create window and apply a Haar like features; a feature extraction unit to extract a set of features from the pre-processed facial image; a classifier to classify the set of features in groups including facial image with and without facial accessories; a control unit comprises an artificial intelligence face acknowledgment model to recognize a face and identify a person with and without facial accessories upon comparing the set of features with an image database stored in a cloud server; and a user interface to show the identified person, wherein the user interface concludes the credibility of the individual's face contingent upon the perceived face certainty level, wherein the higher the certainty level the higher the genuineness of the individual.

Abstract: A metal powder-based manufacturing system is provided and comprises: a sealed vessel defining a manufacturing chamber; a metal transformation/conversion unit contained in the manufacturing chamber and configured to heat a metal-based feedstock for transformation/conversion; an inert gas source in gas communication with the manufacturing chamber to supply inert gas therein, the inert gas source being operatively connected to the manufacturing chamber through an inert gas line; and at least one gas purifying unit in gas communication with the manufacturing chamber to purify the inert gas to obtain a purified inert gas having an oxygen partial pressure below about 100 ppb. A process for transforming/converting metal in a purified inert gas atmosphere.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Disclosed are pressurized surface treatment compositions which impart a microbicidal benefit to treated surfaces which compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a zinc ion source material which releases zinc ions into the treatment composition, preferably a source of Zn++ ions, at least lower alkyl aliphatic monohydric alcohol which independently of other constituents present exhibits a microbicidal effect, a propellant; and, water. The compositions may further optionally include one or more further optional constituents such as a detersive surfactant and/or minor amounts of one or more constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants wherein the compositions have pH of at least 5.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Disclosed are pressurized surface treatment compositions which impart a microbicidal benefit to treated surfaces which compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a zinc ion source material which releases zinc ions into the treatment composition, preferably a source of Zn++ ions, at least lower alkyl aliphatic monohydric alcohol which independently of other constituents present exhibits a microbicidal effect, a propellant; and, water. The compositions may further optionally include one or more further optional constituents such as a detersive surfactant and/or minor amounts of one or more constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants wherein the compositions have pH of at least 5.

Abstract: The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.

Abstract: Disclosed are pressurized surface treatment compositions which impart a microbicidal benefit to treated surfaces which compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a zinc ion source material which releases zinc ions into the treatment composition, preferably a source of Zn++ ions, at least lower alkyl aliphatic monohydric alcohol which independently of other constituents present exhibits a microbicidal effect, a propellant; and, water. The compositions may further optionally include one or more further optional constituents such as a detersive surfactant and/or minor amounts of one or more constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants wherein the compositions have pH of at least 5.